Cancer: Drugs

Department of Health written question – answered on 4th February 2015.

Alert me about debates like this

Photo of Lord Hunt of Kings Heath Lord Hunt of Kings Heath Shadow Spokesperson (Health), Shadow Deputy Leader of the House of Lords

To ask Her Majesty’s Government what was the total level of spending incurred by the Cancer Drugs Fund on reimbursing the National Health Service for molecular diagnostics testing in the last three years for which figures are available.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

Information on expenditure by the Cancer Drugs Fund (CDF) prior to 1 April 2013 is not available at individual drug/indication level.

NHS England has had oversight of the Fund since April 2013 and publishes information on the Fund’s financial position on its website at:

www.england.nhs.uk/ourwork/pe/cdf/

This is also attached.

Only one type of molecular diagnostic has been funded through the CDF since NHS England took over operational management of the Fund in April 2013. RAS (rat sarcoma) testing can be funded though the CDF as a temporary measure while work is currently underway to clarify legacy arrangements for how such tests are currently commissioned and ensure alignment with the National Tariff payment rules.

NHS England has advised that it is currently receiving approximately 350 notifications per month for RAS testing at an estimated cost of £70,000 per month.

CDF Summary Financial Report (PDF Document, 150.77 KB)

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.